Promega and Roche wait for verdict in their patent dispute over the taq enzyme

Promega's patent battle with Roche over the taq enzyme used in the polymerase chain reaction (PCR) process will be decided in the autumn. The trial ended last week with Madison, Wisconsin-based Promega confident that its argument had persuaded the federal district judge in a San Francisco court that Roche's US patent was obtained by fraud.

Promega's patent battle with Roche over the taq enzyme used in the polymerase chain reaction (PCR) process will be decided in the autumn. The trial ended last week with Madison, Wisconsin-based Promega confident that its argument had persuaded the federal district judge in a San Francisco court that Roche's US patent was obtained by fraud.

The judge will now consider written submissions from both sides and a ruling is expected in late summer or early...

More from Archive

More from Medtech Insight